Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06516965

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
346 (actual)
Sponsor
Incyte Corporation · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Conditions

Interventions

TypeNameDescription
DRUGPovorcitinibOral Tablet
DRUGPlaceboOral Tablet

Timeline

Start date
2024-10-10
Primary completion
2026-10-19
Completion
2027-05-03
First posted
2024-07-24
Last updated
2026-04-14

Locations

119 sites across 11 countries: United States, Australia, Belgium, Canada, Chile, Czechia, Germany, Japan, Poland, Spain, United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT06516965. Inclusion in this directory is not an endorsement.

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) (NCT06516965) · Clinical Trials Directory